HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3349-3358

  Ovsyannikova, Inna G ^a   Vierkant, Robert A ^a   Pankratz, V Shane ^a   O'Byrne, Megan M ^a   Jacobson, Robert M ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cytokines; ELISPOT; HLA class I haplotypes; HLA class II haplotypes; HLA supertypes; Rubella vaccine

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA A3 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B7 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MEASLES MUMPS RUBELLA VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ALGORITHM; ARTICLE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GROUPS BY AGE; HAPLOTYPE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INNATE IMMUNITY; LINKAGE ANALYSIS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RUBELLA; SCHOOL CHILD; TH1 CELL; TH2 CELL; VACCINATION;

ADOLESCENT; ADULT; CHILD; CYTOKINES; FEMALE; GENES, MHC CLASS I; GENES, MHC CLASS II; HAPLOTYPES; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; RUBELLA VACCINE; VACCINATION;

EID: 67349084065     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.080     Document Type: Article

References (21)

1. Sarnesto A., Ranta S., Vaananen P., and Makela O. Proportions of Ig classes and subclasses in rubella antibodies. Scand J Immunol 21 3 (1985) 275-282
2. Plotkin S.A., and Reef S.E. Rubella vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. Fourth ed. vol. 26 (2004), Saunders, Philadelphia, PA 707-744
3. Davidkin I., Peltola H., Leinikki P., and Valle M. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Vaccine 18 (2000) 3106-3112
4. Hillary I.B., and Griffith A.H. Persistence of rubella antibody 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine. Vaccine 2 (1984) 274-276
5. Ou D., Mitchell L.A., Ho M., Dćarie D., Tingle A.J., Nepom G.T., et al. Analysis of overlapping T- and B-cell antigenic sites on rubella virus E1 envelope protein. Influence of HLA-DR4 polymorphism on T-cell clonal recognition. Hum Immunol 39 (1994) 177-187
6. Yoo Y.J., Tang J., Kaslow R.A., and Zhang K. Haplotype inference for present-absent genotype data using previously identified haplotypes and haplotype patterns. Bioinformatics 23 18 (2007) 2399-2406
7. Morris R.W., and Kaplan N.L. On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles. Genet Epidemiol 23 3 (2002) 221-233
8. Ovsyannikova I.G., Pankratz V.S., Vierkant R.A., Jacobson R.M., and Poland G.A. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 193 5 (2006) 655-663
9. Sette A., and Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50 3-4 (1999) 201-212
10. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Pankratz V.S., and Poland G.A. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine 25 16 (2007) 3090-3100
11. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., and Poland G.A. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol 65 (2004) 1506-1515
12. Ryan J.E., Ovsyannikova I.G., and Poland G.A. Detection of measles virus-specific interferon-gamma-secreting T-cells by ELISPOT. In: Kalyuzhyny A.E. (Ed). Handbook of ELISPOT: methods and protocols (2005), Humana Press Inc., Totowa, NJ 207-218
13. Sette A., and Sidney J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol 10 (1998) 478-482
14. Sidney J., Southwood S., Mann D.L., Fernandez-Vina M.A., Newman M.J., and Sette A. Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 62 11 (2001) 1200-1216
15. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., and Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70 (2002) 425-434
16. Trachtenberg E., Korber B., Sollars C., Kepler T.B., Hraber P.T., Hayes E., et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 9 7 (2003) 928-935
17. Livingston B.D., Crimi C., Fikes J., Chesnut R.W., Sidney J., and Sette A. Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules. Hum Immunol 60 11 (1999) 1013-1017
18. Tang S.T., Wang M., Lamberth K., Harndahl M., Dziegiel M.H., Claesson M.H., et al. MHC-I-restricted epitopes conserved among variola and other related orthopoxviruses are recognized by T cells 30 years after vaccination. Arch Virol 153 10 (2008) 1833-1844
19. Sidney J., Grey H.M., Kubo R.T., and Sette A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 17 6 (1996) 261-266
20. Sette A., and Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15 4 (2003) 461-470
21. Poland G.A., Ovsyannikova I.G., and Jacobson R.M. Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther 8 11 (2008) 1659-1667